COVID-19, función suprarrenal y corticosteroides

La pandemia por SARS-nCoV-2 elevó muchos interrogantes sobre su efecto en múltiples sistemas. Los datos han sido tomados de infecciones previas por coronavirus, estudios epidemiológicos observacionales y explicaciones que demuestran plausibilidad biológica. El compromiso que produce el virus SARS-nCoV-2 no escapa al campo de la endocrinología y en este documento se consigna la relación que existe entre la función suprarrenal, su respuesta a los procesos infecciosos y el uso de corticosteroides en la COVID-19.

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13. doi: https://doi.org/10.1016/S0140-6736(20)30211-7.
2. Dhama K, Sharun K, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019 – COVID-19. Preprints. 2020;2020030001. doi: 10.20944/ preprints202003.0001.v1.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5.
4. Guerrero J. Para entender la acción del cortisol en inflamación aguda: una mirada desde la glándula suprarrenal hasta la célula blanco. Rev Med Chile. 2017;145(2):230-9. doi: http://dx.doi.org/10.4067/S0034-98872017000200011.
5. Casanueva F, Ghigo E. Hypothalamic Pituitary Diseases. Springer Nature; 2018. doi: https://doi.org/10.1007/978-3-319-44444-4.
6. Melmed S. The Pituitary. 3.a edición. Academic Press; 2010.
7. Slominski RM, Tuckey RC, Manna PR, Jetten AM, Postlethwaite A, Raman C, et al. Extra-adrenal glucocorticoid biosynthesis: implications for autoimmune and inflammatory disorders. Genes Immun. 2020. doi. 10.1038/ s41435-020-0096-6.
8. Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Inmunol. 2011;7(1):13. doi: 10.1186/1710-1492-7-13.
9. Venkatesh B, Imeson L, Kruger P, Cohen J, Jones M, Bellomo R, et al. Elevate plasma – free cortisol concentrations and ratios are associated with increased mortality even in the presence of statin therapy in patients with severe sepsis. Crit Care Med. 2015;43(3):630-5. doi: 10.1097/ CCM.0000000000000750.
10. Marik PE. Critical illness-related corticosteroid insufficiency. Chest. 2009;135(1):181-93. doi: 10.1378/chest.08-1149.
11. Chen HS, Tsai WP, Leu HS, Ho H, Liou L. Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. Rheumatology (Oxford). 2007;46(3):539-44. doi: 10.1093/rheumatology/ kel343.
12. Klein NC, Go Ch, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001;15(2):423-32, vii. doi: 10.1016/s0891- 5520(05)70154-9.
13. Van Everdingen AA, Jacobs JW, Siewertsz DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1- 12. doi:10.7326/0003-4819-136-1-200201010-00006.
14. Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8(2):153-5. doi:10.1016/j.autrev.2008.07.010.
15. World Health Organization. Clinical of Management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance [Internet]. Disponible en: https://apps.who.int/iris/handle/10665/330893.
16. Rusell C, Millar JE, Baillie K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The lancet. 2020;395(10223):473-5. doi: http://doi.org/10.1016/S0140-6736(20)30317-2.
17. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019- nCoV pneumonia. Lancet. 2020;395(10225):683-8. doi: https://doi.org/10.1016/S0140-6736(20)30361-5.
18. Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1414-52. doi: 10.1378/chest.129.6.1441.
19. Saavedra Trujillo CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infectio. 2020;24(3):1-153. doi: http://dx.doi.org/10.22354/in.v24i3.851.
20. Scaroni C, Armigliato M, Cannavo S. COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency? J Endocrinol Invest. 2020;1-2. doi: 10.1007/s40618-020-01253-1.
21. Mebrahtu TF, Morgan AW, Kelley A, Baxter PD, Stewart PM, Pujades-Rodriguez M. Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England. J Clin Endocrinol Metab. 2019;104(9):3757-3767. doi: 10.1210/jc.2019-00153.
22. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine disease: A statement from the European Society of Endocrinology. Endocrine. 2020;69(1):2-5. doi: 10.1007/s12020-020-02294-5.
23. Alextlc.org. COVID-19 :New UK steroid guidance issued. Advice for patients who take replacement steroids (hydrocortisone, prednisolone, dexamethasone or plenadren) for pituitary/adrenal insufficiency [Internet]. Disponible en: https://www.alextlc.org/covid-19-new-uk-steroid-guidance-issued/.
24. Kaiser U, Mirmira RG, Stewart P. Our response to COVID-19 as Endocrinologist and Diabetologist. J Clin Endocrinol Metab. 2020;105(5):dgaa148. doi:10.1210/clinem/dgaa148.
25. Bancos I, Hazeldine J, Chortis V, Hampson P, Taylor AE, Lord JM, et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality. Eur J Endocrinol. 2017;176(4):471-80. doi: 10.1530/EJE-16-0969.

covid-19
pandemia
hormonas de la corteza suprarrenal